Related to Companies Step In to Fill Gap in Enzyme Replacement Therapy for Gaucher’s

• Australian Government Commissions DSM to Build Biomanufacturing Facility
  
• Glycos Biotechnologies to Build Biochemical Plant and R&D Facility in Malaysia
  
• FDA Approves Genzyme Product for Late-Onset Pompe Disease
  
• GSK and EDB Pledge $35M to Augment Green Manufacturing in Singapore
  
• Medicago Wins $21M DARPA Award to Scale Up Production of Flu Vaccines
  
• Lonza Provides GSK with Manufacturing Capacity for Five Clinical-Stage mAbs
  
• SAFC Adds 50,000 Square Feet to Jerusalem Site to Bump Up Fermentation Capabilities
  
• Oxford BioMedica Buys Manufacturing Facility from RecipharmCobra for £1.9M
  
• Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal
  
• FDA Requests More Data from Existing Trials with Protalix’ Gaucher Disease Drug
  
• LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South Korea and Other Emerging Markets
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• EMD Millipore Opens Shanghai Biopharmaceutical Technical Center
  
• Novo Nordisk to Invest $192M in Danish Biopharmaceutical Production Plant
  
• BioMarin Pays $48.5M for Pfizer’s Biologics Production Plant in Ireland
  
• Gilead to Buy Biologics Facility in California from Genentech
  
• Promega Plans 260,000-Square-Foot Facility for Molecular Bio Products
  
• Medicago Achieves Fourth Milestone in Setting Up U.S. cGMP Facility for Plant-Expressed Vaccines
  
• GSK Confirms £500M Investment in Manufacturing Across Multiple U.K. Sites
  
• Baxter to Invest $1B in Construction of New Plasma Products Facility in Georgia